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1. Introduction 
Immunoreactive somatostatin occurs naturally in 
many parts of the body and is known to inhibit the 
secretion of a large number of peptide hormones [ 11. 
Whether or not its physiological actions are entirely 
local is an open question [2] but it has been demon- 
strated by radioimmunoassay that biologically active 
concentrations [3 ] are present in normal human 
plasma after a meal [4]. Somatostatin is known to be 
converted rapidly to a closely related product, [des- 
Ala’]-somatostatin, in rat plasma in vitro and in vivo 
[5]. We can now report that this conversion also 
occurs in human plasma and that the product is equi- 
potent with somatostatin in several biological assay 
systems. 
trifluoroacetic acid (99: 1, by vol.) to acetonitrile/ 
water/trifluoroacetic acid (80: 19: 1, by vol.). The 
eluate was monitored for absorbance at 280 nm and 
peaks were film dried and subjected to amino acid 
analysis after acid hydrolysis. 
2.2. Determination of the potency of (des-Ala’]- 
sornatostatin 
[des-Ala’]-Somatostatin was synthesised by con- 
ventional fragment condensation [6]. Its potency 
was compared with somatostatin: in vivo by measuring 
the serum insulin decrease in the mouse [7] and the 
plasma insulin and glucagon decrease in the rat [8]; 
in vitro by measuring inhibition of growth hormone 
release by rat pituitary cells in culture [9]; and in 
vitro by measuring inhibition of insulin and glucagon 
release from the perfused rat pancreas [lo]. 
2. Experimental 
3. Experimental and results 
2.1, Extraction and purification of peptides 
Following incubation in plasma, peptides were 
extracted and purified using Sephisorb ODS-silica as 
described in [5]. Extraction consists of adsorption of 
hydrophobic peptides onto a small bed of ODS-silica 
in a disposable syringe, followed by elution with 
methanol/water/trifluoroacetic acid (80: 19: 1, byvol.). 
The eluate is diluted with water and loaded onto a 
4 X 250 mm partisil-ODS high-pressure liquid chro- 
matography (HPLC) column. The column was eluted 
with a linear gradient (100 ml total vol.) from water/ 
22 
Cyclic somatostatin (synthesised by conventional 
fragment condensation) was incubated with fresh 
heparinised human plasma and peptides were subse- 
quently extracted using ODS-silica and purified by 
HPLC. The amino acid composition of peptide con- 
tained in the single major peak (see table 1) indicated 
that after 2 min 40% conversion to [des-Ala’]-soma- 
tostatin had taken place. 
Inhibition of the release of insulin, glucagon and 
growth hormone by [des-Ala’]-somatostatin was 
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Table 1 
Amino acid composition of product isolated from human 
plasma following in vitro incubation with somatostatin for 
2 min at 37°C 
- 
Amino acid molar ratios 
Asp 
Theoretical 
(1) 
Control extract Plasma extract 
1.04 1.05 
Thr 
Ser a (3) 
GlY (1) 1 .oo 1.20 
Ala (1) 1.01 0.62 
Cysb (2) 1.36 1.22 
Phe (3) 3.00 3.00 
LYS (2) 2.01 2.04 
Trpb (1) 0.38 0.43 
a Combined estimate due to lack of separation 
b Partially destroyed during acid hydrolysis 
Plasma and a control (pure somatostatin in water) were both 
extracted, purified by HPLC, dried and analysed after acid 
hydrolysis [5] 
assessed and the results are shown in table 2. [des- 
Ala’]-Somatostatin is equipotent with somatostatin 
on release of insulin and glucagon in vivo and on 
release of growth hormone in vitro, and slightly more 
potent on release of insulin and glucagon in vitro. 
4. Discussion 
The biological significance of the conversion 
mechanism is not clear. Rapid conversion in plasma 
of somatostatin to a fully active metabolite suggests 
that whereas somatostatin probably acts in its unmod- 
ified form at the site of release, it is likely that [des- 
Ala’]-somatostatin is the active form in the circula- 
tion. 
Several N-terminally directed antisera presently 
used for the radioimmunoassay of somatostatin (with 
[1251-Tyr1]-somatostatin astracer) have not been 
shown to discriminate between somatostatin and 
[des-Ala’]-somatostatin [ll]. The development of 
selective antisera is essential if the physiological role 
of circulating somatostatin/[des-Ala’]-somatostatin is 
to be evaluated. 
[des-Ala’]-Somatostatin did not markedly differ 
from somatostatin in the above biological tests. How- 
Table 2 
Biological activity of [des-Ala’ ]-somatostatin in hormone 
release 
Assay Potencye (relative to 
somatostatin = 1) 
In vivo decrease of: 
serum insulin, mousea 
plasma insulin, ratb 
plasma glucagon, ratb 
0.97 (0.56-1.66) 
1.14 (0.80-1.67) 
1.05 (0.58-1.94) 
in vitro inhibition of: 
growth hormone release, 
rat pituitary cellsC 
insulin release, rat pancreasd 
0.89 (0.53-1.47) 
1.7 
glucagon release, rat pancreasd 
(1.3 -2.3 ) 
2.3 (1.7 -3.2 ) 
a Determined by radioimmunoassay (RIA) in serum samples 
(N = 28) collected 10 min after sub-cutaneous injection of 
peptides [ 71 
b Determined by RIA in plasma samples (N = 18) collected 
10 min after sub-cutaneous injection of peptides [8] 
’ Determined in culture media [9] (N = 7-9) by means of 
the NIAMDD rat GH RIA kit generously provided by the 
NIAMDD rat pituitary hormone distribution program 
d Determined by RIA in effluent from isolated rat pancreas 
perfused with medium containing 20 nmol arginine/l [lo] 
e Mean (95% fiducial limits in brackets) calculated by 4 point 
assay 
ever, differences in potency may have been masked 
in some tests in vivo by conversion of somatostatin to 
[des-Ala’]-somatostatin before it could reach the tar- 
get cell. It is still conceivable that [des-Ala’l-somato- 
statin may be found to differ from somatostatin in 
its effects on release of peptide hormones other than 
those tested so far. 
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